Pharma
Moderna's Post-COVID Reputation Reset
Moderna's post-COVID rebuild: revenue cliff, mRNA pipeline pivot, individualized cancer vaccine bet, and the brand-narrative challenge of staying credible without a vaccine windfall.
Tag
Stéphane Bancel
Moderna's post-COVID rebuild: revenue cliff, mRNA pipeline pivot, individualized cancer vaccine bet, and the brand-narrative challenge of staying credible without a vaccine windfall.